U.S., June 17 -- ClinicalTrials.gov registry received information related to the study (NCT07650266) titled 'A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma' on June 10.
Brief Summary: The purpose of this study is to find out whether cemiplimab, with or without fianlimab, is an effective treatment for advanced nasopharyngeal carcinoma (NPC), when given with standard chemotherapy drugs gemcitabine and cisplatin before standard chemoradiation.
Study Start Date: July, 2026
Study Type: INTERVENTIONAL
Condition:
Nasopharyngeal Carcinoma
Nasopharyngeal Cancer
Nasopharynx Carcinoma
Nasopharynx Cancer
Intervention:
DRUG: Cemiplimab
Cemiplimab (LIBTAYO) is a PD-1 blocking antibody
DRUG: Fianlimab
Fianlimab is a ...